Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Indivior (Nasdaq/LSE: INDV) has released results from a significant real-world study showing that their extended-release buprenorphine (BUP-XR) treatment demonstrated superior outcomes for opioid use disorder (OUD) patients. The study, published in Drug and Alcohol Dependence Reports, revealed that BUP-XR patients had 57% lower odds of emergency department visits compared to those without medication treatment.
Key findings show that BUP-XR patients experienced significantly lower hospitalization rates (3% vs 5% for daily oral treatment) and notably reduced inpatient costs - nearly five times lower than daily oral buprenorphine patients and ten times lower than untreated patients. Importantly, no opioid overdose-related ED visits were recorded in the BUP-XR group during the six-month study period, compared to 1.2% and 1% overdose rates in other groups.
Indivior (Nasdaq/LSE: INDV) ha pubblicato i risultati di uno studio significativo nel mondo reale, che dimostra come il loro trattamento con buprenorfina a rilascio prolungato (BUP-XR) abbia mostrato risultati migliori per i pazienti con disturbo da uso di oppioidi (OUD). Lo studio, pubblicato su Drug and Alcohol Dependence Reports, ha evidenziato che i pazienti trattati con BUP-XR avevano una probabilità inferiore del 57% di visite al pronto soccorso rispetto a coloro che non ricevevano alcun trattamento farmacologico.
I risultati chiave mostrano che i pazienti con BUP-XR hanno sperimentato tassi di ospedalizzazione significativamente più bassi (3% contro il 5% per il trattamento orale giornaliero) e costi di ricovero notevolmente ridotti - quasi cinque volte inferiori rispetto ai pazienti con buprenorfina orale giornaliera e dieci volte inferiori rispetto ai pazienti non trattati. È importante sottolineare che nel gruppo BUP-XR non sono state registrate visite al pronto soccorso correlate a sovradosaggio da oppioidi durante il periodo di studio di sei mesi, a differenza dei tassi di sovradosaggio dell'1,2% e dell'1% negli altri gruppi.
Indivior (Nasdaq/LSE: INDV) ha publicado los resultados de un estudio significativo en condiciones reales que muestra que su tratamiento con buprenorfina de liberación prolongada (BUP-XR) demostró mejores resultados para pacientes con trastorno por uso de opioides (OUD). El estudio, publicado en Drug and Alcohol Dependence Reports, reveló que los pacientes tratados con BUP-XR tenían un 57% menos de probabilidades de acudir a urgencias en comparación con aquellos sin tratamiento farmacológico.
Los hallazgos clave muestran que los pacientes con BUP-XR experimentaron tasas de hospitalización significativamente más bajas (3% frente al 5% del tratamiento oral diario) y costos hospitalarios notablemente reducidos: casi cinco veces menores que los pacientes con buprenorfina oral diaria y diez veces menores que los pacientes no tratados. Es importante destacar que en el grupo BUP-XR no se registraron visitas a urgencias relacionadas con sobredosis de opioides durante el período de estudio de seis meses, en comparación con tasas de sobredosis del 1,2% y 1% en otros grupos.
Indivior (Nasdaq/LSE: INDV)는 실제 환경에서 진행된 중요한 연구 결과를 발표했습니다. 이 연구는 그들의 장기 지속형 부프레노르핀(BUP-XR) 치료가 오피오이드 사용 장애(OUD) 환자들에게 우수한 결과를 나타냈음을 보여줍니다. Drug and Alcohol Dependence Reports에 게재된 연구에 따르면, BUP-XR 치료를 받은 환자들은 약물 치료를 받지 않은 환자들에 비해 응급실 방문 가능성이 57% 낮았다고 밝혀졌습니다.
주요 결과로는 BUP-XR 환자들이 입원율이 현저히 낮았다(일일 경구 치료군 5% 대비 3%)는 점과 입원 비용이 크게 감소했으며, 이는 일일 경구 부프레노르핀 환자 대비 거의 5배 낮고 치료받지 않은 환자 대비 10배 낮았다는 점입니다. 특히, 6개월 연구 기간 동안 BUP-XR 그룹에서는 오피오이드 과다복용 관련 응급실 방문이 전혀 없었으며, 다른 그룹에서는 각각 1.2%와 1%의 과다복용 비율이 보고되었습니다.
Indivior (Nasdaq/LSE : INDV) a publié les résultats d'une étude importante en conditions réelles montrant que leur traitement par buprénorphine à libération prolongée (BUP-XR) a donné des résultats supérieurs chez les patients souffrant de trouble lié à l'usage d'opioïdes (OUD). L'étude, publiée dans Drug and Alcohol Dependence Reports, a révélé que les patients sous BUP-XR avaient 57 % moins de chances de se rendre aux urgences comparativement à ceux sans traitement médicamenteux.
Les résultats clés montrent que les patients sous BUP-XR ont connu des taux d'hospitalisation significativement plus faibles (3 % contre 5 % pour le traitement oral quotidien) et des coûts d'hospitalisation nettement réduits - presque cinq fois inférieurs à ceux des patients sous buprénorphine orale quotidienne et dix fois inférieurs à ceux des patients non traités. Il est important de souligner qu'aucune visite aux urgences liée à une surdose d'opioïdes n'a été enregistrée dans le groupe BUP-XR pendant la période d'étude de six mois, contre des taux de surdose de 1,2 % et 1 % dans les autres groupes.
Indivior (Nasdaq/LSE: INDV) hat Ergebnisse aus einer bedeutenden Real-World-Studie veröffentlicht, die zeigt, dass ihre langwirksame Buprenorphin-Behandlung (BUP-XR) überlegene Ergebnisse bei Patienten mit Opioidgebrauchsstörung (OUD) erzielt. Die Studie, veröffentlicht in Drug and Alcohol Dependence Reports, zeigte, dass BUP-XR-Patienten 57 % geringere Chancen auf Notaufnahmebesuche hatten als Patienten ohne medikamentöse Behandlung.
Wesentliche Ergebnisse zeigen, dass BUP-XR-Patienten signifikant niedrigere Hospitalisierungsraten aufwiesen (3 % gegenüber 5 % bei täglicher oraler Behandlung) und deutlich reduzierte stationäre Kosten – fast fünfmal niedriger als bei Patienten mit täglicher oraler Buprenorphin-Behandlung und zehnmal niedriger als bei unbehandelten Patienten. Wichtig ist, dass in der BUP-XR-Gruppe während des sechsmonatigen Studienzeitraums keine Notaufnahmebesuche aufgrund von Opioid-Überdosierungen verzeichnet wurden, im Vergleich zu Überdosierungsraten von 1,2 % und 1 % in den anderen Gruppen.
- BUP-XR treatment showed 57% lower odds of emergency department visits compared to no medication treatment
- No opioid overdose-related ED visits recorded in BUP-XR cohort vs 1-1.2% in other groups
- Inpatient costs were 5x lower compared to daily oral treatment and 10x lower than no treatment
- Lower hospitalization rates for BUP-XR patients (3%) versus daily oral treatment (5%)
- BUP-XR cohort had significantly higher overall costs compared to daily oral treatment due to higher pharmacy costs
- Study limited by six-month observation window and may not represent uninsured populations
Insights
Indivior's study shows BUP-XR reduces healthcare utilization and costs versus alternatives, potentially strengthening market position despite higher pharmacy costs.
Indivior's newly published real-world evidence demonstrates significant healthcare utilization advantages for their extended-release buprenorphine (BUP-XR) formulation in treating opioid use disorder (OUD). The data shows patients receiving BUP-XR experienced
The hospitalization metrics are particularly compelling from a healthcare economics perspective. Only
The absence of any opioid overdose-related ED visits in the BUP-XR cohort (versus
However, the economic picture has important nuances. Despite lower emergency and inpatient utilization, BUP-XR's overall costs were similar to no treatment and higher than daily oral therapy – primarily driven by higher pharmacy expenses. The study doesn't clarify whether these higher pharmacy costs stem directly from BUP-XR's pricing or other medications, which creates some uncertainty about the total value proposition.
For Indivior, these findings provide robust clinical and economic evidence to support market access discussions and potentially drive increased adoption of their BUP-XR product, particularly in healthcare systems prioritizing reduced emergency utilization and hospitalization costs.
- Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)
- The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomes
RICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder (OUD) over a six-month follow-up period.
The study found that patients treated with BUP-XR, in the form of the once-monthly long-acting injectable formulation of buprenorphine, had
"Opioid overdose-related ED visits are a critical concern in the ongoing opioid epidemic," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "These findings underscore the clinical and economic value of long-acting injectable treatments of OUD. By reducing ED and physician office visits, BUP-XR may help ease the burden on our healthcare system while supporting long-term recovery outcomes for patients."
The Indivior-funded study also revealed that patients treated with BUP-XR incurred lower inpatient healthcare costs. Inpatient costs for this group were nearly five times lower compared to patients receiving daily oral buprenorphine, and more than 10 times lower compared to patients receiving no MOUD. The BUP-XR cohort did have similar overall all-cause costs compared to the no MOUD cohort and had significantly higher overall costs compared to the daily oral buprenorphine cohort; this was primarily driven by higher outpatient pharmacy costs in the BUP-XR cohort, although it was not possible to determine if the BUP-XR medication itself was driving the difference.
Hospitalization rates for BUP-XR were similarly lower: only
These findings are based on observed claims data and reflect healthcare utilization during the defined study period. Although the results offer valuable insights for public health officials, emergency care providers, and policymakers, the study sample may not fully represent all individuals with OUD, particularly those who are uninsured or outside traditional healthcare systems. Additionally, the six-month observation window may not capture long-term treatment engagement or relapse risk.
The full study is available here: Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients - ScienceDirect
Disclosure:
This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence.
About SUBLOCADE®
SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION
INDICATION
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support.
HIGHLIGHTED SAFETY INFORMATION
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self- administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.
CONTRAINDICATIONS
Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE.
WARNINGS AND PRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.
Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.
Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis.
Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.
Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately.
Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment.
Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE.
Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect.
ADVERSE REACTIONS
Adverse reactions commonly associated with SUBLOCADE (in ≥
For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit www.sublocade.com.
About Opioid Use Disorder (OUD)
Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-real-world-evidence-study-finds-medications-for-opioid-use-disorder-particularly-extended-release-buprenorphine-reduced-odds-of-emergency-department-visits-for-patients-with-opioid-use-disorder-302511427.html
SOURCE Indivior PLC
FAQ
What were the key findings of Indivior's (INDV) real-world study on BUP-XR treatment?
How did hospitalization rates compare between BUP-XR and daily oral treatment in Indivior's study?
What were the overdose rates among different treatment groups in INDV's study?
What were the cost implications of BUP-XR treatment compared to other options?
What are the limitations of Indivior's BUP-XR study?
